Piracetam-d6 is intended for use as an internal standard for the quantification of piracetam by GC- or LC-MS. Piracetam is a nootropic cyclic GABA derivative.1 It is a positive allosteric modulator of AMPA receptors and enhances binding of the NMDA antagonist MK-801 to rat forebrain membranes.2,3 Piracetam (1 mM) protects against amyloid-β-induced decreases in the mitochondrial membrane potential, as well as decreases in neurite outgrowth in the presence of NGF, in PC12 rat adrenal medulla cells.4 It prevents scopolamine-induced amnesia in a passive avoidance test in mice when administered at a dose of 30 mg/kg.5 Formulations containing piracetam have been used in the treatment of myoclonus.
1.Winnicka, K., Tomasiak, M., and Bielawska, A.Piracetam - An old drug with novel properties•Acta Pol. Pharm.62(5)405-409(2005) 2.Copani, A., Genassani, A.A., Aleppo, G., et al.Nootropic drugs positively modulate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal culturesJ. Neurochem.58(4)1199-1204(1992) 3.Hamelin, S.M., and Lehmann, J.C.Effects of putative cognition enhancers on the NMDA receptor by [3H]MK801 bindingEur. J. Pharmacol.281(3)R11-R13(1995) 4.Kurz, C., Ungerer, I., Lipka, U., et al.The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by β-amyloid peptideBr. J. Pharmacol.160(2)246-257(2010) 5.Ghelardini, C., Galeotti, N., Gualtieri, F., et al.The novel nootropic compound DM232 (unifiram) ameliorates memory impairment in mice and ratsDrug Develop. Res.56(1)23-32(2002)